1. Tumor Collection Study: Participants in this research study have newly diagnosed advanced kidney cancer that requires surgery to remove a kidney called a nephrectomy. Argos Therapeutics is conducting a research study of an experimental (investigational) drug (AGS-003) to see if it is effective against kidney cancer. An investigational drug is a medication that is still being studied and has not been approved for use in the general population by the United States Food and Drug Administration (FDA). AGS-003 is made for participants using a piece of their tumors collected after surgical removal of their kidneys. No investigational treatments or procedures will be performed for the tumor collection part of this study. Eligible participants will allow the doctor to take a tumor sample on the day of their scheduled kidney removal surgery. If the doctor examining the removed kidneys determines that participants have a certain type of renal cancer called clear cell, they will be given further information about voluntary participation in the treatment part of the study. 2. Main/Treatment Study: Participants in this research study have newly diagnosed advanced kidney cancer and have previously consented to allow for collection of their tumor samples, which may be used to make personalized experimental drugs for them called AGS-003. Argos Therapeutics is conducting a research study of an experimental (investigational) drug AGS-003 to see if it is effective against kidney cancer. AGS-003 is made for participants by using a piece of their tumors collected after surgical removal of their kidneys along with a certain type of their own white blood cells. The resulting product is a type of immune cell called a dendritic cell, which is very good at activating the immune system against cancer cells. AGS-003 can be used in combination with the approved, regular medications most often prescribed for the treatment of kidne
Participants in this study have recently been diagnosed with a type of leukemia (blood cancer) called chronic myelogenous leukemia (CML). The purpose of this study is to evaluate ponatinib as a potential treatment for patients who have been newly diagnosed with CML. Ponatinib is an experimental anti-cancer drug. This study will compare the effects of ponatinib to another drug called imatinib. Imatinib is approved by the United States Food and Drug Administration (FDA) for treating a variety of human cancers including newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in the chronic phase. This study will enroll approximately 530 participants (subjects) in about 175 centers worldwide.
Karen Parrott, 319-353-6347
If you are 18-75 years old and are in need of a single tooth extraction (excluding molars) you may be eligible to participate in a study about the effectiveness of socket grafting for bone preservation. You must not be pregnant, a smoker, have uncontrolled diabetes, have a history of bisphosphonate use, or any active severe infectious diseases. Compensation is provided. If you are interested or would like more information, please contact Lauren at 319.335.7377, or by email at email@example.com.
Call Lauren at 319.335.7377
Email Lauren at firstname.lastname@example.org
Participants in this research study have been diagnosed with a tumor such as carcinoid, neuroendocrine tumor, neuroblastoma, Ewing's sarcoma, or brain tumor that has cells with special proteins called somatostatin receptors. The purpose of this research study is to see if the tumors can be identified using a special procedure called a positron emission tomography (PET) scan and see if it is as effective as having an Octreoscan and a diagnostic CT. Participants will have an injection with a radioactive drug called 68Gallium-DOTA-tyr3-Octreotide (68Ga-DOTATOC) that binds to tumor cells that have somatostatin receptors and then have a PET scan. A "low dose" computed tomography (CT) scan will then be done on the same scanner. 68Ga-DOTATOC is considered investigational, which means that it has not yet been approved by the U.S. Food and Drug Administration (FDA). The FDA has granted permission to conduct this study under an investigator's new drug (IND) application. About 112 people will take part in this study conducted by investigators at the University of Iowa.
Mary Schall, 319-356-3516
Copyright © 2013 The University of Iowa. All Rights Reserved.